Inhibrx Biosciences, Inc.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Dec 2022 | — | — | $273.9M |
| Jun 2023 | — | — | $192.5M |
| Sep 2023 | — | — | $337.3M |
| Dec 2023 | $264.4M | $307.9M | $277.9M |
| Mar 2024 | — | — | $252.5M |
| Jun 2024 | $39.1M | $258.4M | $226.9M |
| Sep 2024 | $44.1M | $222.6M | $196.3M |
| Dec 2024 | $47.2M | $180.8M | $152.6M |
| Mar 2025 | $148.2M | $242.6M | $216.5M |
| Jun 2025 | $143.6M | $212.1M | $186.6M |
| Sep 2025 | $140.6M | $177.5M | $153.1M |
| Dec 2025 | $138.5M | $146.5M | $124.2M |
| Mar 2026 | $205.0M | $184.0M | $161.7M |
| Jun 2026 | $207.2M | $154.2M | $133.3M |